For IP teams, portfolio managers, competitive intelligence leads, and institutional investors who need to know what the FDA is holding […]
How to FOIA an IND Application: The Complete Pharma Intelligence Playbook Read Post »
1. Why Generic Drug Market Entry Demands a Different Analytical Framework Generic pharmaceutical market entry is not a standard product
For pharma IP teams, portfolio managers, R&D leads, and institutional investors operating in or entering the Russian market. 1. Why
Russia’s Pharmaceutical Patent Term Extensions: The Complete IP Strategy Playbook Read Post »
I. Why This Document Exists Every blockbuster drug that has generated a billion-dollar revenue stream in the past three decades
The $230 Billion Subsidy: How Government Patent Data Drives Biopharma IP Strategy Read Post »
In the early months of the pandemic, when much of the economy was idling, an unusual silence fell over another
Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs Read Post »
Off-patent drugs represent one of the most systematically underexploited categories in the pharmaceutical IP landscape. Their pharmacology is known. Their
A technically dense, data-grounded analysis of repurposing economics, IP valuation, regulatory pathways, computational platforms, and lifecycle management tactics for existing
Drug Repurposing: The Definitive Strategic Guide Read Post »
Why Patents Are the Wrong Starting Point Most analysts open a pharma investment thesis by pulling Orange Book listings and
What Actually Drives Pharma Returns: 10 Non-Patent Factors Every Investor Needs to Model Read Post »
1. Executive Summary FDA approval of a generic drug is a regulatory milestone, not a commercial launch date. The gap
Get fresh news and insights, drug patent expirations & more…
